BAXTER INTERNATIONAL INC

NYSE: BAX·Deerfield, Illinois·

Price
$25.54
Base IV
$27.71

Valuation snapshot

Below base case

At $25.54, the price sits between our bear case ($7.01) and base case ($27.71).

Values per share, from an .

No growth
…
Loading earnings power
Base case
$27.71
above today's price · range $7.01–$50.56
Price vs base case
8% below
$25.54 against $27.71
Base casevalued by DCF
Price vs base
Priceclose 11‑16

The price has risen 8.7% since this valuation was struck on 2026-11-01, so some of the gap opened up after these figures were set.

Whisker on the base case runs bear $7.01 to bull $50.56. Values per share.

Price against each value

Bear case
$7.01
Price 264% above
No growth
…
—
Base case
$27.71
Price 8% below
Researched bygemini-3.8-flash-medium
Valuation Nov 1, 2026 · Price as of Nov 16, 2026How we got here

What does Baxter International do?

Baxter provides hospitals and healthcare facilities with intravenous solutions, infusion systems, surgical equipment, and pharmaceuticals to manage patient care and treatment.

It brought in $11.6B of sales in the 12 months to Sep 2026.

Led by Andrew Hider, President and Chief Executive Officer since 2025. Baxter International Inc. Form 8-K

Baxter VIAFLO IV solution bagImage: Baxter International
Industry
Healthcare
Based in
Deerfield, Illinois
Trades on
NYSE as BAX

Here is where each dollar a customer pays ends up. For every $1 of sales in the 12 months to Sep 2026, it spent about $1.06, so it lost 6¢ on each dollar. The biggest cost is making what it sells, 70¢ of every dollar.

$1 of sales
  • Making what it sells70¢
  • Research and development4¢
  • Sales, marketing and admin25¢
  • Everything else it takes to operate2¢
  • Tax4¢
  • Other items after tax1¢
  • Lost on each dollar−6¢
Totals of the four quarters to Sep 2026, from the company's own filings. The split by product is from the latest fiscal year.

Who pays Baxter International, and for what?

Baxter sells medical products and therapies, hospital equipment and monitoring systems, and injectable and inhaled medicines. It makes money by selling these products and related services to healthcare providers and patients in more than 100 countries.

Its customers include hospitals, clinics, care centers, distributors, governments, and patients using home therapies under medical supervision.

  • Medical Products & Therapies

    47%

    Sterile IV solutions, infusion systems and supplies, nutrition therapies, and surgical products.

    Baxter VIAFLO IV solution bagImage: Baxter International
  • Healthcare Systems & Technologies

    27%

    Connected care products, smart beds, patient monitors, respiratory devices, and surgical equipment.

  • Pharmaceuticals

    22%

    Injectable medicines, inhaled anesthetics, and drug compounding services.

  • Other

    3%

    Primarily transition and manufacturing services related to the sale of Kidney Care, plus contract manufacturing.

Share of the latest fiscal year's sales, as the company reports it.

Where its work physically happens, beyond headquarters:

  • North Cove plant — Marion, United States. This major IV solutions plant is critical to Baxter’s supply, and hurricane damage there disrupted production and affected financial results.
  • Cleveland plant — Cleveland, United States. The plant produces IV containers and medication reconstitution devices, with Baxter reporting capacity of about 3.4 million units a day.
  • Round Lake campus — Round Lake, United States. The campus manufactures pharmaceuticals and drug delivery products, making it an important production site for Baxter’s Pharmaceuticals segment.
  • Guayama plant — Guayama, United States. The plant produces IV solutions and inhaled anesthesia products that support Baxter’s hospital and pharmaceutical supply.
  • Alliston plant — Alliston, Canada. The plant manufactures IV fluids for Canadian patients and has also supplied the U.S. during an IV fluid shortage.
See them on the globe

Baxter International Inc. 2025 Form 10-K

How is the business doing?

Sales have barely moved over 5 years, from $11.7B in 2020 to $11.2B in 2025.

It spends more to run the business than it brings in: an operating loss of 2¢ per sales dollar.

Sales$11.2B
20162025
Operating margin-3%
20162025
Each bar is one fiscal year (2016–2025), summed from four published quarters; the latest is highlighted.

What does management say it's aiming for?

Baxter says its mission is to save and sustain lives.

“Save and Sustain Lives.”

Baxter Reports Second-Quarter 2026 Results

Who is responsible for the plan?

  • Andrew HiderPresident and Chief Executive Officer

    He oversees Baxter's global operations, corporate strategy, and comprehensive portfolio of medical technologies and therapies. Baxter generates revenue by manufacturing and selling essential medical devices, intravenous products, pharmaceuticals, and connected care systems globally.

  • Maria Cecilia SorianoGroup President, Infusion Therapies & Technologies and Pharmaceuticals

    She oversees the operational, commercial, and product strategies for Baxter's Infusion Therapies & Technologies and Pharmaceuticals divisions. These product divisions make money through the production and sale of intravenous delivery sets, infusion pumps, clinical nutrition, and specialty injectable pharmaceuticals.

Roles checked November 14, 2026.

What management says it is working on now:

Net leverage, By the end of 2026
Approximately 3.0x
Baxter International Inc. 2025 Form 10-K
Organic sales growth, Full year 2026
2% to 3%
Baxter Reports Second-Quarter 2026 Results
Adjusted diluted earnings per share, Full year 2026
$1.95 to $2.15
Baxter Reports Second-Quarter 2026 Results
Adjusted operating margin, Full year 2026
13% to 14%
Baxter International (BAX) Q2 2026 Earnings Call Transcript
Goals in management's own numbers. A target is a promise, not a result.

What's changing right now?

Growth is holding steady. In Q3 2026 it sold 5% more than a year earlier. The year before, quarters averaged 5%.

Its operating margin is wider than a year ago: 8¢ per sales dollar, against 6¢.

Since Oct 2026 the share price has risen 9%, from $23.50 to $25.54.

Bull $50.56Base $27.71Bear $7.01Oct 30Nov 16 · $25.54
Daily closing prices we have recorded, set against our bear-to-bull range. Our price records start October 30, 2026.

Recently

Coming up

  • Timing uncertain; hold was in effect as of the 2025 annual report

    Novum IQ pump correction and distribution hold

    The timing for lifting the U.S. and Canadian shipment and installation hold remains uncertain. Baxter expects no meaningful Novum IQ large-volume pump sales while the hold is in effect.

    Baxter International Inc. 2025 Form 10-K
  • After the 2025 Corporate Responsibility Report; date not specified

    2026 Corporate Responsibility goals

    Baxter expects to announce refreshed corporate responsibility commitments and goals after publishing its 2025 report, either separately or as part of its 2026 report.

    Baxter International Inc. 2025 Form 10-K

Our own estimate moved too: the base case went from $21.07 to $27.71 a share between our last two valuations.

What could go wrong?

No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.

  1. Product safety and quality

    Problems with product quality or manufacturing can lead to recalls, costs, and lost sales. Baxter's Novum IQ infusion pumps have had safety corrections, and U.S. and Canadian distribution and installation of the large-volume pump were paused pending further corrections.

    From the company's own filingsWould hit how fast sales growBaxter International Inc. 2025 Form 10-K

  2. Competition and pricing

    Rivals compete on price, service, product performance, and innovation. Hospital purchasing groups and customer consolidation can increase discount demands and make it harder to raise prices.

    From the company's own filingsWould hit how fast sales growBaxter International Inc. 2025 Form 10-K

  3. Supply and manufacturing disruptions

    Shortages or delays in materials, components, manufacturing, or delivery can limit sales and raise costs. Some inputs come from single-source suppliers, and replacement suppliers may take time to qualify.

    From the company's own filingsWould hit how much of each sale it keepsBaxter International Inc. 2025 Form 10-K

  4. Debt and financial flexibility

    Baxter had about $9.48 billion of debt at the end of 2025. Repaying it uses cash that could otherwise support research, investment, or other business plans, and missing its debt goal could raise borrowing costs.

    From the company's own filingsWould hit how much it has to reinvestBaxter International Inc. 2025 Form 10-K

  5. Regulation and reimbursement

    Many products need government approval before sale and remain subject to inspection and oversight. Changes to approval rules, healthcare payments, or pricing policies could delay launches, limit sales, or reduce revenue.

    From the company's own filingsWould hit how fast sales growBaxter International Inc. 2025 Form 10-K

  6. Tariffs and economic uncertainty

    Baxter says tariffs and inflation have raised costs, while long-term customer contracts can limit how quickly it passes those costs on. Economic weakness may also lead customers to delay orders or reduce hospital spending.

    From the company's own filingsWould hit how much of each sale it keepsBaxter Reports Second-Quarter 2026 Results

  7. Quarterly YoY growth decelerated to 2.90% in Q1 2026, demonstrating potential variability across quarters.

    From our researchWould hit how fast sales growBaxter Q1 2026 Form 10-Q

  8. Fourth quarter GAAP operating margins were negative in 2024 (-15.80%) and 2025 (-24.51%) due to non-cash charges and restructuring.

    From our researchWould hit how much of each sale it keepsBaxter 2025 Form 10-K

Is it a good business?

From 2016 to 2025 it earned between -9% and 15% on the capital invested in it, a median of 6%. Its cost of capital in the latest valuation is 6.6%; returns were above it in 4 of the 9 years.

From 2016 to 2025 it earned between -42% and 60% on its shareholders' equity, a median of 13%.

Over 10 years its operating margin ranged from 15¢ to 16¢ per sales dollar, a median of 10¢. Gross margin ran from 30¢ to 43¢.

derived computed from the filingsassumption cost of capital from the latest valuation
Return on invested capital-2%
20162025

Cost of capital 6.6%

Return on equity-16%
20162025
Return on invested capital is operating profit after tax (at the median effective rate, 14%) over debt plus equity less cash at each fiscal year end. Return on equity is net income over equity. Both are computed from published quarters.

The number of shares has held roughly steady over the past year.

What might it be worth?

The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .

Today a share costs $25.54. Our put its value between $7.01 and $50.56, with $27.71 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .

Bear case, $7.01

This scenario assumes that hospital budget constraints and rising import duties slow annual sales growth to under two percent while ongoing restructuring costs keep business profits below historical double-digit levels.

Base case, $27.71

This scenario assumes that steady hospital demand for medical supplies and newly launched infusion systems maintains annual sales expansion around four percent while core business profitability gradually recovers toward historical norms.

Bull case, $50.56

This scenario assumes that strong adoption of digital hospital equipment and specialized injectable medications accelerates annual sales growth above five percent while manufacturing efficiency drives profitability back toward peak performance.

Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.

Why the gap?

The price and our value are close.Margin of safety: 8%

For Baxter International to be worth today's $25.54, sales would need to grow about 2.5% a year. We assume 3.6%. Over the last 5 years, sales shrank 1.4% a year.

−2%0%+2%+4%+6%Past 5 yrs −1.4%Price needs 2.5%We assume 3.6%

Or, if sales grow 3.6% as we assume, the price works with a profit margin of 10.9% (we assume 11.5%).

Keep in mind: a gap this small is normal. A small change in almost any assumption would close it.

Do you think sales can grow 2.5% a year?

Try your own numbers

We're moderately sure of this range: it scores 51 out of 100 on our checks. The weakest point is terminal-value dependency.

Test the assumptions

Our base value of $27.71 rests on three assumptions. Change any of them to see how the value per share responds.

  • Revenue growth, 5-year average3.6%
  • Operating margin11.5%
  • Long-term growth rate2.5%

This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.

Base estimate

$27.71 8.5%

Build